Relaxing of regulations for regenerative medicines has cascading effect internationally, new research warns
Researchers warn that if just one country decides to relax regulations in the field, a heightened sense of competition can spur others to do the same.
It’s unclear whether this deregulation best serves competition, science or the patients.
Regenerative medicine focuses on developing therapies to regenerate or replace injured, diseased or defective cells, tissues or organs, like stem cell ‘treatments’.
Due to the use of living cells, it can be hard to set regulations in the same way as for other drugs so differences in the rules can occur.
But, according to Professor Margaret Sleeboom-Faulkner from the University of Sussex and Douglas Sipp, from the RIKEN Centre for Developmental Biology (CDB), Kobe, Japan, one thing that should always be maintained is efficacy – the ability to reliably produce a certain therapeutic result.
Professor of Social & Medical Anthropology, Margaret Sleeboom-Faulkner said: “Regenerative medicine contains a lot of economic promise, and there’s already been enormous investments into it.”
“While this is good in terms of focusing on new and innovative treatments to improve healthcare, it also leaves the field particularly vulnerable to regulatory brokerage. When one country relaxes their regulations, others are tempted to do the same in order to ‘keep up’.”
“Competition is the last way we want medicine to be progressing.”
The paper, published today in the journal Science, uses the example of South Korea as the first country to give preferential regulatory treatment to stem cell medicine. Their decision to issue a flurry of three stem cell-based medical products between 2011-12, and a fourth in 2014, attracted international scepticism for sacrificing clinical data standards in exchange for speed to market.
Yet Japan, who had launched a multi-billion dollar initiative to lead the world in regenerative medicine, began to see South Korea as a competitor. This resulted in a change of Japanese law in 2013, to allow regenerative medicine products a faster entry to the market.
Professor Sleeboom-Faulkner explained: “The International Society for Stem Cell Research has published general guidelines around regenerative medicines but countries regulate it in different ways.”
“At the moment, Britain has the safety net of the EU stamp on its regulations. While we’re not expecting to lose that, with Brexit looming we could see new interpretations of the existing guidelines and find ourselves starting to compete with other countries too.
“The UK has a reputation for high standards in medicine regulation and should continue to uphold this and be vigilant in the face of political pressures for eye-catching innovation.”
Professor Sleeboom-Faulkner also notes that strict regulations can have a negative impact too, making things hard for developing countries who have to import equipment and resources. As a result, strict regulations can cause some lower income countries to relax the implementation of their regulations and take measures to be able to catch up. Of late, however, it is the wealthy countries that have become more permissive.
Professor Sleeboom-Faulkner said: “What’s needed is a greater awareness that the regulations of one country can have cascading effects internationally.
“Regenerative medicines are often trialled on patients with a terminal illness, so it’s hard to know the precise effect of all of this. With less stringent clinical trials and the fast-tracking of ‘treatment’, we’d assume standards are slipping and risks increase, but it’s hard to prove that.”
“Ideally, regulations should be internationally coordinated and there should be a collaborative global approach in order to maintain basic standards.”
Professor Sleeboom-Faulkner is urging countries to be cautious when it comes to developing treatments particularly in the face of deviant ventures such as the recent case of gene-edited foetuses in China, and the current trend of increasing flexibilities in regulations internationally.
The Latest on: Regenerative medicine regulation
via Google News
The Latest on: Regenerative medicine regulation
- RenovaCare Awarded New Patents Allowing Greater Versatility of SkinGun™; Sterility in Field ...on November 20, 2020 at 1:25 am
Our newest patents broaden the potential use of our novel SkinGun™ to spray an array of drugs, hormones, medical solutions and other agents. Further, these patented inventions enable the SkinGun™ ...
- Stem Cell Clinic in Colombia Offers Hope to International Pain Patientson November 15, 2020 at 12:12 am
By A. Rahman Ford, PNN Columnist As the U.S. Food and Drug Administration continues to restrict access to stem cell therapy with its overly burdensome regulations, Americans with chronic pain continue ...
- MSc Tissue Engineering for Regenerative Medicineon November 14, 2020 at 11:18 am
Prepare for PhD study, specialist clinical training or a career in related industries, including pharmaceutical, biotechnology and regenerative medicine sectors ... You can find regulations and ...
- Doctors, patients pressure FDA to regulate commercial stem cell clinicson November 8, 2020 at 4:00 pm
Opponents of the regulation worry that the proposal ... a chain of clinics specializing in adult stem cell regenerative medicine. Lawrence Goldstein, Ph. D., director of the Sanford Stem Cell ...
- California Voters Weigh In On Stem Cells, Dialysis, Property Taxes And Moreon November 7, 2020 at 5:32 am
23: California Measure To Stiffen Regulations At Dialysis Clinics ... an infusion of cash for the California Institute for Regenerative Medicine, known as CIRM, for stem cell studies and trials.
- iPSC-derived NK cells maintain high cytotoxicity and enhance in vivo tumor control in concert with T cells and anti–PD-1 therapyon November 4, 2020 at 12:13 pm
3 Department of Medicine, Division of Regenerative Medicine ... effective to target tumor cells that have alterations in antigen presentation or HLA down-regulation. Such alterations are presumed to ...
- Election guide: California propositions on the 2020 balloton October 27, 2020 at 12:43 pm
Authorizes $5.5 billion in state general obligation bonds to fund grants from the California Institute of Regenerative Medicine to educational ... Restricts local regulation of app-based drivers ...
- BMS6398 Principles of Regenerative Medicine and Tissue Engineering (15 credits)on October 25, 2020 at 2:56 pm
This unit will provide students with an overview of the multidisciplinary concepts underpinning tissue engineering. Through detailed examples of tissue engineering strategies for replacing specific ...
- Aims of BIONETon October 19, 2020 at 7:18 pm
Advanced biological and biomedical research focusing in particular upon reproductive and regenerative medicine, clinical trials and the ... and to explore key issues of the ethical regulation of ...
- Framework for the Regulation of Regenerative Medicine Productson August 13, 2020 at 5:37 pm
Expedited Programs for Regenerative Medicine Therapies for Serious Conditions Evaluation of Devices Used with Regenerative Medicine Advanced Therapies The final guidance on expedited programs ...
via Bing News